Cancer Pharmacokinetics and Pharmacodynamics Facility

点击翻译按钮获取中文摘要

Abstract: Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) The Hillman Cancer Center (HCC) Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) is an important shared resource that supports science conducted by the HCC research programs and has a major impact on cancer drug development on a national level by providing state-of-the-art and comprehensive quantitative and qualitative bioanalytical support for preclinical and clinical cancer therapeutic studies. The activities of CPPF have earned national recognition for its exceptional service in developing and delivering PK and PD analyses of investigational agents. CPPF: (1) provides extensive pharmacology expertise to investigators by assisting in PK and PD study design and sample collection; (2) develops and provides quality-assured/quality-controlled quantitative and qualitative assay capabilities for rapid and efficient PK and PD bioanalyses; and (3) integrates PK/PD data through sophisticated data analyses. CPPF is located in two contiguous lab spaces with a shared office pod in the HCC Research Pavilion. Major equipment includes 3 Waters QuattroMicro LC-MS/MS, 2 SCIEX4000 LC-MS/MS (1 hybrid linear ion-trap), 2 HPLC-UV/FL/DAD, 1 HPLC-UV/RAD, 1 atomic absorption spectrometer, a LICOR Odyssey infra-red scanner, a Tecan Infinite Microplate Reader, and a Nexcelom Cellometer K2 Cell counter. Ancillary equipment includes -20 °C and -80 °C freezers, a nitrogen generator, and an uninterrupted power supply, as well as access to shared instrumentations including a liquid scintillation counter. CPPF is directed by Drs. Jan Beumer, Professor of Pharmaceutical Sciences and Medicine, and John Schmitz, Associate Professor of Medicine, and is overseen by an HCC Advisory Committee made up of HCC members. Dr. Beumer leads and Dr. Schmitz actively participates in the weekly Merrill Egorin Translational Research meeting, where HCC early drug development projects are discussed by an inter- disciplinary group of basic, translational, and clinical scientists, thereby ensuring appropriate consideration of CPPF’s role in these projects. During this funding period, CPPF analyzed samples for a total of 36 unique investigators and provided support for all 7 HCC research programs. During this funding period, CPPF developed 37 new assays, an average of 22 assays were used per year, and more than 30,000 samples were analyzed (excluding calibrators, quality controls or assay validation samples). CPPF supported 30 peer-reviewed grants and 70 publications, 30 of which were focused on clinical trials, and 19 of which focused on development of novel assay methodologies.